Survanta Suspension
NDC Package 0074-1040-08

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Survanta (beractant) suspension is sURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. This formulation utilizes a suspension delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-1040 and is authorized under FDA application BLA020032.

Identification & Billing

NDC Package Code
0074-1040-08
Package Description
1 VIAL, SINGLE-USE in 1 CARTON / 8 mL in 1 VIAL, SINGLE-USE
Product Code
0074-1040
11-Digit Billing Format
00074104008
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Survanta
Non-Proprietary Name
Beractant
Substance Name
Beractant
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Endotracheal - Administration directly into the trachea.
Active Ingredient(s)
BERACTANT 25 mg/mL
Usage Information
SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants.

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA020032
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
07-01-1991
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0074-1040). Click a package code to view its specific billing and regulatory data.

0074-1040-04
1 VIAL, SINGLE-USE in 1 CARTON / 4 mL in 1 VIAL, SINGLE-USE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-1040-08 identifies a specific commercial package of 1 vial, single-use in 1 carton / 8 ml in 1 vial, single-use of Survanta, a human prescription drug labeled by Abbvie Inc.. This suspension is formulated for endotracheal use and contains beractant as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on July 01, 1991. The current certification is valid through December 31, 2026.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074104008. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-1040-08
11-Digit CMS (5-4-2)
00074-1040-08

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.